On October 8, Recursion Pharmaceuticals, Inc. fell 8.08% in regular trading, trading at $3.9111/share, with Turnover of $38.0443 million.

The decline followed disclosures that the company's amended agreement with Tempus AI removed its right to unilaterally terminate for convenience, replaced up to $84 million in discretionary payments over two years with $42 million in committed payments over three years, and coincided with insider sales by directors Borgeson Blake and Hershberg Robert, which collectively pressured market sentiment.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that integrates technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery, with a pipeline spanning cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, and other candidates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)